Last Updated: 2026

PTC Therapeutics

Rank#3029

Market Cap5.40B

CountryUnited States

Summary

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

History

PTC Therapeutics was founded in 1998 by its President & CEO Stuart Peltz, Ph.D., and some of his colleagues from the University of Medicine and Dentistry of New Jersey (UMDNJ) and from Princeton University. Over the past two decades, PTC has been dedicated to the discovery and development of treatments for rare diseases and the development of innovative modalities to treat serious and life-threatening diseases.

Mission

PTC is focused on the discovery and development of innovative therapies that improve the quality of life of patients who, in many cases, have limited or no access to appropriate treatment. We strive to improve the lives of patients through research and development and to be a key partner in the fight against rare and life-threatening diseases.

Vision

We envision a world in which all patients have equal access to therapies that are tailored to their needs and designed with their interests in mind. We strive to be the leading global provider of treatments for rare and life-threatening diseases and the trusted partner of physicians and patients in the fight against these diseases.

References

https://en.wikipedia.org/wiki/PTC_Therapeutics

https://in.investing.com/equities/ptc-therape

https://finance.yahoo.com/quote/PTCT/profile?p=PTCT

https://www.crunchbase.com/organization/ptc-therapeutics

https://sec.report/CIK/0001070081

https://companiesmarketcap.com/

https://www.ptcbio.com

Leadership team

Dr. Stuart W. Peltz Ph.D. (Co-Founder, CEO & Exec. Director)

Dr. Allan Steven Jacobson Ph.D. (Co-Founder, Chairman of Scientific Advisory Board & Independent Director)

Ms. Emily Luisa Hill (Chief Financial Officer)